Study: inhalable HPV vax could be more effective; Vical, GeomIdea ink deal

Vaccine Research

A new study has stated that a targeted inhalable dry powder HPV vaccine may prove more effective and less costly than the current commercial human papillomavirus (HPV) vaccine used throughout the world. News

Vical Incorporated has entered into an evaluation and supply agreement with GenomIdea, a subsidiary of AnGes MG, for the development of a DNA vaccine for livestock against pandemic influenza. Funding for the project is provided under a grant from "The Okinawa New Industry Creation Research & Development Support Business," supported by the Okinawa Industry Promotion Public Corporation. Vical release

The first clinical trial for a vaccine against the most widespread strain of malaria, Plasmodium vivax, is now under way at the Walter Reed Army Institute for Research (WRAIR), near Washington, DC. The BBC's Jane O'Brien speaks with those heading the trial and individuals who are being bitten by infected mosquitoes to help further the research. News

A national effort to assure that potential HIV vaccines are reliably tested will be housed at Duke University Medical Center, with a $52.8 million, seven-year grant from the National Institutes of Health. Item

Vaccine Market

Boehringer Ingelheim Vetmedica is proposing to create 78 new jobs in Fort Dodge and add three buildings at its Fifth Street Northwest facility to expand its research capabilities. The maker of animal drugs and vaccines is also proposing to add more jobs in Ames and Sioux Center, according to a plan to be considered by the Iowa Economic Development Board on Thursday. Article

Merck's Gardasil vaccine appears effective for preventing anal cancer, members of a U.S. advisory panel said on Wednesday. The FDA advisers did not take any votes on the the product, but most said Gardasil was shown effective in company studies. Story

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.